Document Detail

Vascular reactivity during the development of two-kidney, one-clip Goldblatt hypertension in conscious dogs.
MedLine Citation:
PMID:  7165847     Owner:  NLM     Status:  MEDLINE    
This study evaluates the sequential changes in vascular reactivity in conscious dogs during the early and late phases of two-kidney, one-clip Goldblatt hypertension (2-KGH) produced by unilateral renal artery constriction (URAC). The in vivo responses to serotonin (5-HT), norepinephrine (NE), angiotensin II (Ang II), prostacyclin (PGI2), acetylcholine (ACH), and nitroglycerin (GTN) were reproducible and stable throughout the 32-day period of study in dogs subjected to sham URAC. The vascular responses to 5-HT, Ang II, and PGI2 were enhanced day 1 post-URAC, before mean arterial pressure (MAP), cardiac output (CO), or total peripheral resistance (TPR) increased. The magnitude of the enhanced reactivity progressed on days 4 and 32 post-URAC, as hypertension developed. The pressor responses to NE did not change from pre-URAC values until CO and MAP were elevated. The vasodepressor responses to ACH and GTN diminished over a 12-day period post-URAC, in parallel with the change in CO, but prior to any increase in TPR. These data suggest that in dogs with 2-KGH changes in vascular reactivity precede the development of the increased MAP and TPR of hypertension. The lack of uniformity of the onset of the reactivity changes to the different agonists suggests that both intrinsic factors and pressure changes modify the vascular wall in the early and later stages of 2-KGH.
S Greenberg; C McGowan; M Gaida
Related Documents :
11814137 - The hypertension-lipid connection: insights into the relation between angiotensin ii an...
12399257 - Increased dietary sodium alters neural control of blood pressure during intravenous ang...
15450107 - Pressure-independent cardiac effects of angiotensin ii in pigs.
7630117 - Upregulation of angiotensin ii type 1 receptor gene expression in chronic renovascular ...
23569637 - Metabolic risk factor reduction through a worksite health campaign: a case study design.
22661897 - Critical evaluation of the efficacy and tolerability of azilsartan.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Canadian journal of physiology and pharmacology     Volume:  60     ISSN:  0008-4212     ISO Abbreviation:  Can. J. Physiol. Pharmacol.     Publication Date:  1982 Dec 
Date Detail:
Created Date:  1983-05-05     Completed Date:  1983-05-05     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0372712     Medline TA:  Can J Physiol Pharmacol     Country:  CANADA    
Other Details:
Languages:  eng     Pagination:  1482-92     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin II / pharmacology
Blood Pressure / drug effects
Cardiac Output / drug effects
Hemodynamics / drug effects*
Hypertension, Renal / physiopathology*
Muscle, Smooth, Vascular / drug effects,  physiopathology*
Norepinephrine / pharmacology
Pressoreceptors / physiology
Serotonin / pharmacology
Vascular Resistance / drug effects
Vasodilator Agents / pharmacology
Grant Support
Reg. No./Substance:
0/Vasodilator Agents; 11128-99-7/Angiotensin II; 50-67-9/Serotonin; 51-41-2/Norepinephrine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Reflex control of arterial compliance in rabbits.
Next Document:  Net urate reabsorption in the Dalmatian coach hound with a note on automated measurement of urate in...